Novan Announces Strategic Priorities and Outlines Key Milestones

<div class="b2iNewsItemBodyDiv"><link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /><p align="center"><em>- </em><em>Company planning for three potential New Drug Application (NDA) filings in three years with the first submission expected in Q3 2022 for lead program SB206 in molluscum contagiosum </em><em>-</em></p> <p align="center"><em>- </em><em>Late-stage product candidate, SB204 for the treatment of acne vulgaris, selected to advance as second...